Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eileen M Boyle

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
Blood|November 28, 2014
Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocationsCharlotte Pawlyn, Lorenzo Melchor, Alex Murison, et al.
Blood Cancer Journal|June 20, 2020
Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patternsCarolina Schinke, Eileen M Boyle, Cody Ashby, et al.
Cancer|August 14, 2014
IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myelomaEileen M Boyle, Guillemette Fouquet, Stéphanie Guidez, et al.
Current Research in Translational Medicine|April 24, 2021
PHF19 inhibition as a therapeutic target in multiple myelomaCarolina D Schinke, Jordan T Bird, Pingping Qu, et al.
Leukemia|August 8, 2021
Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroupsEileen M Boyle, Adam Rosenthal, Hussein Ghamlouch, et al.
Genes, Chromosomes & Cancer|October 8, 2014
A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myelomaEileen M Boyle, Paula Z Proszek, Martin F Kaiser, et al.
Nature Communications|January 13, 2021
The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myelomaEileen M Boyle, Shayu Deshpande, Ruslana Tytarenko, et al.
Nature Communications|April 24, 2015
APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myelomaBrian A Walker, Christopher P Wardell, Alex Murison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2023
Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple MyelomaEileen M Boyle, Patrick Blaney, James H Stoeckle, et al.
British Journal of Haematology|June 21, 2019
Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trialEileen M Boyle, Xavier Leleu, Marie-Odile Petillon, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Blood|November 28, 2014
Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocationsCharlotte Pawlyn, Lorenzo Melchor, Alex Murison, et al.
Blood Cancer Journal|June 20, 2020
Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patternsCarolina Schinke, Eileen M Boyle, Cody Ashby, et al.
Cancer|August 14, 2014
IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myelomaEileen M Boyle, Guillemette Fouquet, Stéphanie Guidez, et al.
Current Research in Translational Medicine|April 24, 2021
PHF19 inhibition as a therapeutic target in multiple myelomaCarolina D Schinke, Jordan T Bird, Pingping Qu, et al.
Leukemia|August 8, 2021
Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroupsEileen M Boyle, Adam Rosenthal, Hussein Ghamlouch, et al.
Genes, Chromosomes & Cancer|October 8, 2014
A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myelomaEileen M Boyle, Paula Z Proszek, Martin F Kaiser, et al.
Nature Communications|January 13, 2021
The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myelomaEileen M Boyle, Shayu Deshpande, Ruslana Tytarenko, et al.
Nature Communications|April 24, 2015
APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myelomaBrian A Walker, Christopher P Wardell, Alex Murison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2023
Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple MyelomaEileen M Boyle, Patrick Blaney, James H Stoeckle, et al.
British Journal of Haematology|June 21, 2019
Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trialEileen M Boyle, Xavier Leleu, Marie-Odile Petillon, et al.
Pageof 6